Travere director sells 10K shares after option exercise

Q: What insider transactions did TVTX director Gary A. Lyons report on this Form 4?

Gary A. Lyons reported exercising options for 10,000 TVTX shares at $17.44 and selling 10,000 shares in multiple tranches at weighted-average prices between about $62.53 and $64.16 on August 17–18, 2026.

Q: Were Gary A. Lyons’ August 2026 TVTX stock sales under a Rule 10b5-1 plan?

Yes. The filing states the sales were made under a written plan adopted May 18, 2026 that meets the requirements of Rule 10b5-1(c), indicating they were pre-arranged rather than discretionary at the time of sale.

Q: What option terms applied to the TVTX shares Gary A. Lyons exercised?

The options Lyons exercised covered 10,000 shares of Travere Therapeutics common stock at an exercise price of $17.44 per share and were described as fully vested and exercisable with an expiration date of May 17, 2027.

Q: At what prices did Gary A. Lyons sell his TVTX shares?

Lyons’ reported TVTX sales used weighted-average prices of $62.5289, $63.4999, $64.1620, $63.2659, and $63.8557 per share, with each tranche having its own detailed intraday price range disclosed in the footnotes.

Q: How many Travere Therapeutics (TVTX) shares did Gary A. Lyons sell versus exercise?

According to the transaction summary, Lyons exercised options for 10,000 shares and sold 10,000 shares of common stock over the two days, resulting in a net reported 10,000-share sale across the Form 4 transactions.

Travere Therapeutics, Inc. (TVTX) director Gary A. Lyons reported an exercise-and-sell sequence over August 17–18, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) director Gary A. Lyons reported an exercise-and-sell sequence over August 17–18, 2026. He exercised stock options for 10,000 shares of common stock at an exercise price of $17.44 per share (options fully vested and expiring May 17, 2027), acquiring 10,000 shares. He then sold 10,000 shares of common stock in multiple tranches at weighted-average prices ranging from about $62.53 to $64.16 per share. All sales were made pursuant to a written trading plan adopted on May 18, 2026 under Rule 10b5-1(c).

Insider Trade Summary 10b5-1

Exercise and Sale: 10,000 shares ($458K approx. pre-tax spread)

Exercise and Sale 9 txns

Insider LYONS GARY A

Role Director

Sold 10,000 shs ($633K)

Approx. gross sale proceeds $633K

Approx. exercise cost $174K

Approx. pre-tax spread $458K

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy) ^F7	5,000	$0.00	$0.00
Exercise	Common Stock	5,000	$17.44	$87K
Sale	Common Stock ^{F1, F5}	4,100	$63.2659	$259K
Sale	Common Stock ^{F1, F6}	900	$63.8557	$57K
Exercise	Stock option (right to buy) ^F7	5,000	$0.00	$0.00
Exercise	Common Stock	5,000	$17.44	$87K
Sale	Common Stock ^{F1, F2}	1,900	$62.5289	$119K
Sale	Common Stock ^{F1, F3}	2,600	$63.4999	$165K
Sale	Common Stock ^{F1, F4}	500	$64.162	$32K

Holdings After Transaction: Stock option (right to buy) — 0 contracts (Direct); Common Stock — 61,500 shares (Direct)

Footnotes (7)

F1. This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
F2. The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3. The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4. The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5. The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6. The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7. The stock option is fully vested and exercisable.

Key Figures

Options exercised: 10,000 shares Shares sold: 10,000 shares Option exercise price: $17.44 per share +5 more

8 metrics

Options exercised 10,000 shares Stock options exercised into common stock on August 17–18, 2026

Shares sold 10,000 shares Total common shares sold across all sale transactions

Option exercise price $17.44 per share Exercise price for stock options converted into common stock

Weighted-average sale price tranche 1 $62.5289 per share August 17, 2026 sale; prices ranged from $62.00 to $62.95

Weighted-average sale price tranche 2 $63.4999 per share August 17, 2026 sale; prices ranged from $63.01 to $63.94

Weighted-average sale price tranche 3 $64.1620 per share August 17, 2026 sale; prices ranged from $64.04 to $64.25

Weighted-average sale price tranche 4 $63.2659 per share August 18, 2026 sale; prices ranged from $62.76 to $63.69

Weighted-average sale price tranche 5 $63.8557 per share August 18, 2026 sale; prices ranged from $63.77 to $64.01

Key Terms

Rule 10b5-1(c), weighted average sale price, stock option, fully vested and exercisable

4 terms

Rule 10b5-1(c) regulatory

"plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $62.5289"

stock option financial

"consists of the sale of shares underlying a stock option granted to the Reporting Person"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

fully vested and exercisable financial

"The stock option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TVTX director Gary A. Lyons report on this Form 4?

Gary A. Lyons reported exercising options for 10,000 TVTX shares at $17.44 and selling 10,000 shares in multiple tranches at weighted-average prices between about $62.53 and $64.16 on August 17–18, 2026.

Were Gary A. Lyons’ August 2026 TVTX stock sales under a Rule 10b5-1 plan?

Yes. The filing states the sales were made under a written plan adopted May 18, 2026 that meets the requirements of Rule 10b5-1(c), indicating they were pre-arranged rather than discretionary at the time of sale.

What option terms applied to the TVTX shares Gary A. Lyons exercised?

The options Lyons exercised covered 10,000 shares of Travere Therapeutics common stock at an exercise price of $17.44 per share and were described as fully vested and exercisable with an expiration date of May 17, 2027.

At what prices did Gary A. Lyons sell his TVTX shares?

Lyons’ reported TVTX sales used weighted-average prices of $62.5289, $63.4999, $64.1620, $63.2659, and $63.8557 per share, with each tranche having its own detailed intraday price range disclosed in the footnotes.

How many Travere Therapeutics (TVTX) shares did Gary A. Lyons sell versus exercise?

According to the transaction summary, Lyons exercised options for 10,000 shares and sold 10,000 shares of common stock over the two days, resulting in a net reported 10,000-share sale across the Form 4 transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/19/2026 - 04:05 PM Accepted by SEC EDGAR 08/19/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LYONS GARY A

(Last)

(First)

(Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/17/2026		M		5,000	A	$17.44	66,500	D
Common Stock	08/17/2026		S⁽¹⁾		1,900	D	$62.5289⁽²⁾	64,600	D
Common Stock	08/17/2026		S⁽¹⁾		2,600	D	$63.4999⁽³⁾	62,000	D
Common Stock	08/17/2026		S⁽¹⁾		500	D	$64.162⁽⁴⁾	61,500	D
Common Stock	08/18/2026		M		5,000	A	$17.44	66,500	D
Common Stock	08/18/2026		S⁽¹⁾		4,100	D	$63.2659⁽⁵⁾	62,400	D
Common Stock	08/18/2026		S⁽¹⁾		900	D	$63.8557⁽⁶⁾	61,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$17.44	08/17/2026		M			5,000	⁽⁷⁾	05/17/2027	Common Stock	5,000	$0	5,000	D
Stock option (right to buy)	$17.44	08/18/2026		M			5,000	⁽⁷⁾	05/17/2027	Common Stock	5,000	$0	0	D

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.

2. The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

3. The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

5. The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

6. The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

7. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR